Liver biopsy is the gold standard for best characterisation of chronic liver disease. Liver biopsy has largely been replaced by non invasive tests such as fibroscan. Fibroscan is not routinely available, has to be maintained by specialised systems and expensive for people in low and middle income countries. APRI and FIB-4 are recognised parameters that have been validated for assessment of liver fibrosis, which can effectively replace the need to use fibroscan in more than 50% of cases. This